Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Dbr1em1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Dbr1em1flox/Cya

Common Name
Dbr1-flox
Product ID
S-CKO-18167
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-83703-Dbr1-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Dbr1-flox Mouse (Catalog S-CKO-18167) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Dbr1-flox
Strain ID
CKOCMP-83703-Dbr1-B6J-VB
Gene Name
Dbr1
Product ID
S-CKO-18167
Gene Alias
--
Background
C57BL/6JCya
Gene Full Name
debranching RNA lariats 1
Modification
Conditional knockout
NCBI ID
83703 (Mouse)
Phenotype
MGI:1931520
Chromosome
Chr 9 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000066650
NCBI Transcript ID
NM_031403
Target Region
Exon 3~5
Size of Effective Region
~2.4 kb
Overview of Gene Research
Dbr1, short for RNA DEBRANCHING ENZYME 1, is a rate-limiting enzyme in the lariat intronic RNA (lariRNA) decay process. During pre-mRNA splicing, introns are removed as branched lariat RNAs, and Dbr1 debranches them in the rate-limiting step of lariat turnover. This process is crucial for intron recycling and likely regulates the production of translation-competent mRNAs [2,3,5].

In plant studies, sequestration of Dbr1 into stress granules (SGs) by SICKLE (SIC) enhances lariRNA accumulation, which promotes the transcription of heat-stress tolerance genes, highlighting its role in plant heat-stress responses [1]. In human cells, Dbr1 depletion leads to a 20-fold increase in lariats and increased exon skipping, indicating its role in proper splicing and spliceosome recycling [3,5]. Inherited DBR1 deficiency in humans is associated with brainstem viral encephalitis, as DBR1-deficient cells have impaired stress granule assembly, which in turn impairs PKR-mediated antiviral immunity [4,6]. A founder DBR1 variant also causes a lethal form of congenital ichthyosis [7]. In esophageal squamous cell carcinoma, lower DBR1 expression is associated with a worse prognosis [8].

In summary, Dbr1 is essential for lariat intronic RNA decay, which impacts mRNA processing, intron turnover, and splicing. Studies on Dbr1-related genetic models, such as human DBR1-deficient cases, have revealed its importance in various biological processes and disease conditions, including plant heat-stress tolerance, viral encephalitis, congenital ichthyosis, and esophageal squamous cell carcinoma prognosis.

References:
1. Wu, Chengyun, Wang, Xingsong, Li, Yan, Song, Chun-Peng, Hu, Zhubing. 2024. Sequestration of DBR1 to stress granules promotes lariat intronic RNAs accumulation for heat-stress tolerance. In Nature communications, 15, 7696. doi:10.1038/s41467-024-52034-w. https://pubmed.ncbi.nlm.nih.gov/39227617/
2. Mohanta, Arundhati, Chakrabarti, Kausik. 2020. Dbr1 functions in mRNA processing, intron turnover and human diseases. In Biochimie, 180, 134-142. doi:10.1016/j.biochi.2020.10.003. https://pubmed.ncbi.nlm.nih.gov/33038423/
3. Buerer, Luke, Clark, Nathaniel E, Welch, Anastasia, Mosammaparast, Nima, Fairbrother, William G. 2024. The debranching enzyme Dbr1 regulates lariat turnover and intron splicing. In Nature communications, 15, 4617. doi:10.1038/s41467-024-48696-1. https://pubmed.ncbi.nlm.nih.gov/38816363/
4. Chan, Yi-Hao, Lundberg, Vanja, Le Pen, Jérémie, Ekwall, Olov, Zhang, Shen-Ying. 2024. SARS-CoV-2 brainstem encephalitis in human inherited DBR1 deficiency. In The Journal of experimental medicine, 221, . doi:10.1084/jem.20231725. https://pubmed.ncbi.nlm.nih.gov/39023559/
5. Buerer, Luke, Clark, Nathaniel E, Welch, Anastasia, Mosammaparast, Nima, Fairbrother, William G. 2023. The debranching enzyme Dbr1 regulates lariat turnover and intron splicing. In Research square, , . doi:10.21203/rs.3.rs-2931976/v1. https://pubmed.ncbi.nlm.nih.gov/37398028/
6. Ru, Shuo, Tang, Sisi, Xu, Hui, Zhang, Shen-Ying, Gao, Daxing. 2024. Human DBR1 deficiency impairs stress granule-dependent PKR antiviral immunity. In The Journal of experimental medicine, 222, . doi:10.1084/jem.20240010. https://pubmed.ncbi.nlm.nih.gov/39636299/
7. Shamseldin, Hanan E, Sadagopan, Mukunth, Martini, Javier, Bertoli-Avella, Aida, Alkuraya, Fowzan S. 2023. A founder DBR1 variant causes a lethal form of congenital ichthyosis. In Human genetics, 142, 1491-1498. doi:10.1007/s00439-023-02597-3. https://pubmed.ncbi.nlm.nih.gov/37656279/
8. Xu, Xiaoqin, Yang, Xin, Liu, Xue, Cheng, Xiaolong, Xi, Yanfeng. . The Role of DBR1 as a Candidate Prognosis Biomarker in Esophageal Squamous Cell Carcinoma. In Technology in cancer research & treatment, 21, 15330338221083105. doi:10.1177/15330338221083105. https://pubmed.ncbi.nlm.nih.gov/35244467/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research